Home » Newsletters » BioWorld Science

BioWorld Science

June 22, 2006

View Archived Issues

BTG closes busy year

AZD-2171, combined with chemotherapy or EGFR inhibitor, is active in patients with solid tumors

Focus on BAY-579352 at ASCO

ISTA licenses new investigational glaucoma products from Senju

NeoRx changes name to Poniard Pharmaceuticals

Epeius awarded grant to support cancer gene therapy trials with Rexin-G

MQX-503 studied in European trial for Raynaud's phenomenon

Exenatide snapshots from the American Diabetes Association annual meeting

Synergistic weight loss seen with bupropion/naltrexone combination

Galiximab/rituximab combination feasible and active in non-Hodgkin's lymphoma

GDNF gene therapy is neuroprotective in Huntington's disease / News in Context

Discovery and potential preclinical antiobesity efficacy of PSN-632408, a GPR119 agonist

NicOx granted generic name naproxcinod for HCT-3012

Phase Ia study of Reolysin with radiation completes enrollment

ARQ-501 enters phase II development

New phase II study investigates PXD-101 for mesothelioma

Aeolus selects AEOL-11207 as first development candidate

New preclinical findings for CF-101

U.K. acute pain study of cannabinor cleared to begin

Praecis ceases efforts to license or sell Plenaxis

Three-hour imaging time point most appropriate for ThromboView

Immunological bioactivity and antiviral properties of VGV-1 confirmed

Lenalidomide study snapshots from the European Hematology Association congress

Study evaluates AVE-7688 pharmacodynamics

Cardioprotective activity of first generation inhibitor of malonyl-CoA decarboxylase

Orphan drug designation for Anthim

Remicade sBLA in psoriatic arthritis accepted for filing

Recent patents describe new therapeutic strategies for endocrine-related disorders

Novel antibacterial agents disclosed in two recent Pfizer patents

New fixed-dose formulations for BPH described in recent GSK patent

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...